{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:23:21Z","timestamp":1768011801523,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.ahj.2018.03.012","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T18:30:40Z","timestamp":1522348240000},"page":"39-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients\u2013Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial"],"prefix":"10.1016","volume":"202","author":[{"given":"Erin A.","family":"Bohula","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin M.","family":"Scirica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Fanola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Keech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Abrahamsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce H.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfeng","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"Perdomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Satlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen D.","family":"Wiviott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2018.03.012_bb0005","series-title":"(WHO) obesity and overweight fact sheet","author":"World Health Organization","year":"2016"},{"issue":"8","key":"10.1016\/j.ahj.2018.03.012_bb0010","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/jama.2014.732","article-title":"Prevalence of childhood and adult obesity in the United States, 2011-2012","volume":"311","author":"Ogden","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ahj.2018.03.012_bb0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJM199908053410607","article-title":"Guidelines for healthy weight","volume":"341","author":"Willett","year":"1999","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ahj.2018.03.012_bb0020","doi-asserted-by":"crossref","first-page":"481","DOI":"10.7326\/0003-4819-122-7-199504010-00001","article-title":"Weight gain as a risk factor for clinical diabetes mellitus in women","volume":"122","author":"Colditz","year":"1995","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.ahj.2018.03.012_bb0025","doi-asserted-by":"crossref","first-page":"961","DOI":"10.2337\/diacare.17.9.961","article-title":"Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men","volume":"17","author":"Chan","year":"1994","journal-title":"Diabetes Care"},{"issue":"23","key":"10.1016\/j.ahj.2018.03.012_bb0030","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1000367","article-title":"Body-mass index and mortality among 1.46 million white adults","volume":"363","author":"Berrington de Gonzalez","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ahj.2018.03.012_bb0035","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa066254","article-title":"Effects of bariatric surgery on mortality in Swedish obese subjects","volume":"357","author":"Sjostrom","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ahj.2018.03.012_bb0040","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.2011.1914","article-title":"Bariatric surgery and long-term cardiovascular events","volume":"307","author":"Sjostrom","year":"2012","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.ahj.2018.03.012_bb0045","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.116.025629","article-title":"Weight loss and heart failure: a nationwide study of gastric bypass surgery versus intensive lifestyle treatment","volume":"135","author":"Sundstrom","year":"2017","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ahj.2018.03.012_bb0050","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ahj.2018.03.012_bb0055","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMoa1112082","article-title":"Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects","volume":"367","author":"Carlsson","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ahj.2018.03.012_bb0060","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ahj.2018.03.012_bb0065","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects","volume":"363","author":"James","year":"2010","journal-title":"N Engl J Med"},{"issue":"9740","key":"10.1016\/j.ahj.2018.03.012_bb0070","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(10)60935-X","article-title":"Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial","volume":"376","author":"Topol","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ahj.2018.03.012_bb0075","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jama.2012.9931","article-title":"Cardiovascular risk assessment in the development of new drugs for obesity","volume":"308","author":"Hiatt","year":"2012","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ahj.2018.03.012_bb0080","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Multicenter, placebo-controlled trial of lorcaserin for weight management","volume":"363","author":"Smith","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ahj.2018.03.012_bb0085","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","article-title":"A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial","volume":"96","author":"Fidler","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ahj.2018.03.012_bb0090","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/oby.2012.66","article-title":"Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study","volume":"20","author":"O'Neil","year":"2012","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"10.1016\/j.ahj.2018.03.012_bb0095","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4103\/0976-500X.130158","article-title":"Lorcaserin: a novel antiobesity drug","volume":"5","author":"Brashier","year":"2014","journal-title":"J Pharmacol Pharmacother"},{"key":"10.1016\/j.ahj.2018.03.012_bb0100","series-title":"Lorcaserin prescriber information","year":"2012"},{"key":"10.1016\/j.ahj.2018.03.012_bb0105","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc13-S011","volume":"36","year":"2013","journal-title":"Diabetes Care"},{"issue":"9850","key":"10.1016\/j.ahj.2018.03.012_bb0110","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0140-6736(12)61269-0","article-title":"Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 degrees P-TIMI 50 trial","volume":"380","author":"Scirica","year":"2012","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.ahj.2018.03.012_bb0115","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"issue":"45","key":"10.1016\/j.ahj.2018.03.012_bb0120","first-page":"1061","volume":"46","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"10.1016\/j.ahj.2018.03.012_bb0125","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery versus intensive medical therapy for diabetes\u20145-year outcomes","volume":"376","author":"Schauer","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ahj.2018.03.012_bb0130","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Look","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ahj.2018.03.012_bb0135","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jama.2016.1558","article-title":"Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ahj.2018.03.012_bb0140","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1740774514561243","article-title":"Protecting the confidentiality of interim data: addressing current challenges","volume":"12","author":"Fleming","year":"2015","journal-title":"Clin Trials"},{"issue":"4","key":"10.1016\/j.ahj.2018.03.012_bb0145","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ahj.2018.03.012_bb0150","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.molmet.2017.07.004","article-title":"Lorcaserin improves glycemic control via a melanocortin neurocircuit","volume":"6","author":"Burke","year":"2017","journal-title":"Mol Metab"},{"issue":"5","key":"10.1016\/j.ahj.2018.03.012_bb0155","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/oby.21798","article-title":"Effect of lorcaserin on glycemic parameters in patients with type 2 diabetes mellitus","volume":"25","author":"Magkos","year":"2017","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"10.1016\/j.ahj.2018.03.012_bb0160","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1172\/JCI70678","article-title":"Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs","volume":"123","author":"Meltzer","year":"2013","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.ahj.2018.03.012_bb0165","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/jpet.107.133348","article-title":"Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization","volume":"325","author":"Thomsen","year":"2008","journal-title":"J Pharmacol Exp Ther"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318300875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318300875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:00:09Z","timestamp":1757570409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870318300875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":33,"alternative-id":["S0002870318300875"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2018.03.012","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients\u2013Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2018.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}